Giampiero Carosi

Summary

Affiliation: University of Brescia
Country: Italy

Publications

  1. ncbi Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report
    A Matteelli
    Clinic of Infectious and Tropical Diseases University of Brescia, Italy
    J Chemother 10:474-5. 1998
  2. ncbi Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Clin Lab Anal 15:43-6. 2001
  3. ncbi Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Clin Lab Anal 15:127-30. 2001
  4. ncbi [New strategies and new drugs in the salvage therapy for HIV infection]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Med Clin (Barc) 118:222-4. 2002
  5. ncbi Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
  6. ncbi Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
  7. ncbi Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
  8. doi Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a
    Paola Nasta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS 22:857-61. 2008
  9. ncbi Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
  10. doi Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection
    Monia Mendeni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Clin Infect Dis 52:1164-73. 2011

Detail Information

Publications81

  1. ncbi Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report
    A Matteelli
    Clinic of Infectious and Tropical Diseases University of Brescia, Italy
    J Chemother 10:474-5. 1998
    ..We report the case of a clarithromycin resistant disseminated M. avium infection in an AIDS patient, acquired after long term monotherapy with clarithromycin for the treatment of cryptosporidiosis...
  2. ncbi Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Clin Lab Anal 15:43-6. 2001
    ..Twelve of our patients (12.9%) had no mutation encoding drug resistance and were completely sensitive to all RT and protease inhibitors. Therefore, not all virological failures are caused by HIV-1 genomic resistance...
  3. ncbi Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients
    E Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Clin Lab Anal 15:127-30. 2001
    ..The development of more precise resistance tests and interpretations are needed for better control of HIV replication. Other metabolic/pharmacokinetics factors of poor drug adherence should also be assessed...
  4. ncbi [New strategies and new drugs in the salvage therapy for HIV infection]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Med Clin (Barc) 118:222-4. 2002
  5. ncbi Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
    ..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...
  6. ncbi Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
    ..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)...
  7. ncbi Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
    ..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...
  8. doi Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a
    Paola Nasta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS 22:857-61. 2008
    ..To investigate the association between insulin resistance and rapid virologic response...
  9. ncbi Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
    ..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure...
  10. doi Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection
    Monia Mendeni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Clin Infect Dis 52:1164-73. 2011
    ..There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF...
  11. ncbi Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 21:92-9. 2007
    ..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)...
  12. ncbi Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 74:29-33. 2004
    ....
  13. ncbi Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis
    Alberto Matteelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 52:64-9. 2009
    ..Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment. We determined variations over time of the pharmacokinetic parameters of NVP in patients who receive RFM...
  14. doi Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis
    Francesca Gatti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Antimicrob Chemother 63:575-8. 2009
    ..Liver stiffness at baseline and alanine aminotransferase levels at baseline and during follow-up were measured in order to find a correlation between drug levels and liver fibrosis or hepatotoxicity...
  15. ncbi Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Curr HIV Res 6:43-8. 2008
    ..Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness...
  16. ncbi Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3
    Giuseppe Lapadula
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    Antivir Ther 12:941-7. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously...
  17. doi Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis
    Giuseppe Lapadula
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 80:747-53. 2008
    ..38; 95% CI:0.17-0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed...
  18. doi Screening and Management of HIV-2-Infected Individuals in Northern Italy
    Silvia Costarelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Brecia, Italy
    AIDS Patient Care STDS 22:489-94. 2008
    ..Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients...
  19. ncbi Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
  20. ncbi Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART
    Maria Cristina Uccelli
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Ann Nutr Metab 50:247-52. 2006
    ..Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet...
  21. ncbi Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    J Antimicrob Chemother 56:190-5. 2005
    ....
  22. ncbi Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Int J Antimicrob Agents 29:185-90. 2007
    ..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk...
  23. ncbi Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy
    Eugenia Quiros-Roldan
    Infectious Diseases Clinic, University of Brescia, Italy
    J Clin Lab Anal 16:76-8. 2002
    ..A slow decline in the detectability of mutations encoding NNRTI resistance was found...
  24. ncbi Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 10:505-13. 2005
    ....
  25. doi HIV-related liver disease: ARV drugs, coinfection, and other risk factors
    Massimo Puoti
    Department of Infectious and Tropical Diseases, University of Brescia, AO Spedali Civili, Brescia, Italy
    J Int Assoc Physicians AIDS Care (Chic) 8:30-42. 2009
    ..As more information about the mechanisms of drug related liver injury is known, clinicians will be better able to tailor therapies to suit individual situations, resulting in greater patient safety and outcomes...
  26. ncbi Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Intervirology 47:350-4. 2004
    ....
  27. ncbi Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Med Sci Monit 9:CS16-9. 2003
    ..Resistance testing on the proviral genome has been suggested in order to detect the presence of archived resistance mutations and to guide drug prescription...
  28. ncbi Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Viral Immunol 17:279-86. 2004
    ....
  29. ncbi Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Health Policy 65:261-7. 2003
    ..To assess the impact of highly active antiretroviral therapy (HAART) on health resource utilisation (HRU) and to estimate associated direct costs in a population based setting...
  30. pmc Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy)
    Ilaria Izzo
    Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    BMC Public Health 11:124. 2011
    ..Therefore, we examined pregnant women by regional provenance and measured variables that could be associated with detectable HIV RNA at delivery...
  31. doi Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop
    Giampiero Carosi
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Dig Liver Dis 43:259-65. 2011
    ....
  32. ncbi Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  33. ncbi Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients
    Alberto Matteelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Curr HIV Res 5:349-53. 2007
    ..These results suggest that a dose of 800 mg of EFV in association with rifampicin may be appropriate for patients of weight > 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF...
  34. ncbi Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    J Infect Dis 188:194-201. 2003
    ..52-5.52; P=.001; RetroGram: OR, 2.34; 95% CI, 1.21-4.55; P=.012), whereas, in contrast to real or virtual phenotype, interpretations according to biological cut-offs were not (OR, 1.91; 95% CI, 0.77-4.76; P=.162)...
  35. ncbi Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  36. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  37. doi High prevalence of radiological vertebral fractures in HIV-infected males
    Carlo Torti
    Institute of Infectious and Tropical Diseases, School of Medicine, University of Brescia, P le Spedali Civili, 1, 25123 Brescia, Italy
    Endocrine 41:512-7. 2012
    ..Furthermore, proactive diagnosis of vertebral fragility fractures is particularly relevant in patients who are overweight or suffer from diabetes...
  38. ncbi Hepatitis A in men having sex with men (MSMs) in northern Italy
    Alessandro Pini
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    Infez Med 18:113-4. 2010
    ..Some of our HAV cases occurred in HIV-infected subjects. This observation underlines the action of HAV as a sexually transmitted infection and urges preventive measures, such as routine HAV vaccination in the HIV-infected population...
  39. pmc Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance
    Manuela Fogli
    Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, Spedali Civili Square, 25123 Brescia, Italy
    Clin Dev Immunol 2012:829584. 2012
    ..These results provide new insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4⁺ T cell decline...
  40. ncbi QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants
    Anna C C Carvalho
    Institute of Infectious and Tropical Diseases, University of Brescia, Piazza Spedali Civili 1, 25125 Brescia, Italy
    J Infect 55:164-8. 2007
    ..A new test for LTBI identification that uses more specific antigens of Mycobacterium tuberculosis is now commercially available under the brand name of QuantiFERON-TB Gold test...
  41. doi Hepatitis B virus and HIV coinfection in low-income countries: unmet needs
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia, Italy
    Clin Infect Dis 46:367-9. 2008
  42. ncbi Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Massimo Puoti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:627-30. 2004
    ..In summary, use of pegylated interferon appears to increase the risk of non-respiratory infections independently from neutropenia...
  43. ncbi Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Francesca Gatti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Rev 9:16-24. 2007
    ....
  44. ncbi Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study
    Andrea Patroni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 3:451-61. 2002
    ..Lipid disturbances have also been associated with hepatitis C virus (HCV) chronic infection in HIV-uninfected participants. HAART-induced lipid abnormalities may then have peculiar features in HIV-HCV co-infected individuals...
  45. doi Adherence to hand hygiene in an Italian long-term care facility
    Angelo Pan
    Institute of Tropical and Infectious Diseases, Spedali Civili, University of Brescia, Brescia, Italy
    Am J Infect Control 36:495-7. 2008
    ..8%) but significantly lower than that reported in an infectious disease unit (53.7%; P < .0001). Our findings indicate that compliance with HH is a similar problem in LTCFs as in acute care facilities...
  46. ncbi The burden of HIV and hepatitis C virus coinfection
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia, Brescia, Italy
    Curr Opin HIV AIDS 2:460-5. 2007
    ..Persons with HIV are frequently coinfected with hepatitis C virus. We review recent data on the epidemiology and natural history of hepatitis C in HIV-infected persons...
  47. ncbi [The novel non-A, non-E hepatitis viruses and their pathogenic effect]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, Spedali Civili, Brescia, Italy
    Med Clin (Barc) 122:552-4. 2004
    ..Only a careful evaluation of the data and the scientific concordance of all the evidence will resolve the question of whether they are only commensal viruses or pose a real pathogenic potential...
  48. ncbi Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents
    Francesco Castelli
    Institute for Infectious and Tropical Diseases, School of Medicine and Dentistry, University of Brescia, Brescia, Italy
    Digestion 73:109-18. 2006
    ..The addition of loperamide or other antimotility agents usually provides symptom relief and further shortens the duration of illness and may be therefore safely adopted in the healthy adult unless dysentery is present...
  49. ncbi Chlamydia trachomatis genital infection in migrant female sex workers in Italy
    Alberto Matteelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Piazza Spedali Civili, I 25125 Brescia, Italy
    Int J STD AIDS 14:591-5. 2003
    ..trachomatis genital infection in migrant sex workers. Women from Eastern Europe have a significantly higher risk. These data reinforce the need for targeted control interventions...
  50. ncbi Linezolid for the treatment of central nervous system infections in neurosurgical patients
    Pierluigi Viale
    Clinic of Infectious and Tropical Diseases, University of Brescia, Italy
    Scand J Infect Dis 34:456-9. 2002
    ....
  51. ncbi A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regi
    Carlo Torti
    Institute for Infectious and Tropical Diseases, Brescia, Italy
    Clin Infect Dis 40:1828-36. 2005
    ....
  52. doi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  53. ncbi Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients
    Mario Clerici
    Cattedra di Immunologia, Universita degli Studi di Milano, DISP LITA Vialba, Milano, Italy
    AIDS 16:1767-73. 2002
    ..Control of HIV replication can be observed in highly active antiretroviral therapy (HAART)-treated and, occasionally, in HAART-naive patients. The immunological correlates of these situations were examined in a longitudinal study...
  54. ncbi Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Instituto di Ricerca e Cura a Carattere Scientifico, San Matteo Hospital, University of Pavia, Italy
    J Acquir Immune Defic Syndr 46:297-303. 2007
    ..This study was designed to investigate the incidence and type of liver-related complications and mortality in coinfected cirrhotic patients...
  55. doi Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients
    Giuseppe Lapadula
    Clin Infect Dis 46:1127-9. 2008
  56. ncbi Haemostatic activation in HIV infected patients treated with different antiretroviral regimens
    Angelo Pan
    Istituto di Malattie Infettive e Tropicali, Spedali Civili, Universita di Brescia, Brescia, Italy
    Curr HIV Res 6:70-6. 2008
    ..In conclusion, a) HIV infection per se may alter the haemostatic markers of cardiovascular risk, b) minor differences were observed among the different classes of HIV infected patients, namely between NNRTI and PI treated patients...
  57. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  58. ncbi Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study
    Maria Mercedes Santoro
    University of Tor Vergata, Rome, Italy
    AIDS Patient Care STDS 22:7-16. 2008
    ..The antiviral efficacy of atazanavir is greater when boosted with low-dose ritonavir...
  59. ncbi Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
    Asda Vibhagool
    Medicine Department, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand
    Curr Med Res Opin 20:1103-14. 2004
    ..a regimen containing the protease inhibitor indinavir (IDV) 800 mg three times daily plus COM twice daily (IDV/COM) in antiretroviral-naïve, HIV-infected patients...
  60. ncbi Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations
    Carlo Torti
    J Acquir Immune Defic Syndr 35:324-6. 2004
  61. ncbi Genotypic resistance tests in the management of the HIV-infected patient at virological failure
    Antonio Aceti
    Department of Infectious Diseases, University of Rome La Sapienza, Rome, Italy
    Scand J Infect Dis Suppl 106:61-6. 2003
    ..The rationale and advantages of using such testing after first virological failure will be discussed...
  62. ncbi SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression
    Eugenia Quiros-Roldan
    Department of Infectious and Tropical Diseases, Spedali Civili of Brescia, 25123, Italy
    AIDS Res Hum Retroviruses 19:1079-82. 2003
    ..At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation...
  63. ncbi Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial
    Francesco Mazzotta
    Department of Infectious Diseases, S M Annunziata Hospital, ASL Firenze, Italy
    J Acquir Immune Defic Syndr 32:268-80. 2003
    ..Several factors should be considered to take better advantage of resistance testing, including treatment history, clinical status, and patients' ability to adhere to treatment...
  64. ncbi Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome
    Massimo Puoti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, Italy
    J Acquir Immune Defic Syndr 32:259-67. 2003
    ..To assess incidence, risk factors, histology, and outcome of severe hepatotoxicity (SH) during antiretroviral treatment (ART)...
  65. ncbi Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:419-20. 2002
  66. ncbi Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali Università degli Studi di Brescia AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:324-32. 2002
    ..The search for the perfect treatment continues...
  67. ncbi Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin
    Francesca Moretti
    AIDS 16:1440-2. 2002
  68. ncbi No evidence of benefical effect of GB virus type C infection on the course of HIV infection
    Eugenia Quiros-Roldan
    AIDS 16:1430-1. 2002
  69. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
    ....
  70. ncbi [Usefulness of pharmacokinetics in the management of antiretroviral therapy]
    Eugenia Quiros-Roldan
    Med Clin (Barc) 124:695-6. 2005
  71. ncbi CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
    Carlo Torti
    Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    J Antimicrob Chemother 59:1141-7. 2007
    ..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination...
  72. ncbi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
    ..g., ENF) for triple-class-experienced patients...
  73. ncbi Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma
    Antivir Ther 11:233-43. 2006
    ..To evaluate antiviral efficacy of stavudine/tenofovir (d4T/TDF) backbone combination in late-line antiretroviral therapy, and to assess clinical and virological determinants of treatment success...
  74. ncbi Vaginal colonization with Candida spp. in human immunodeficiency virus-infected women: a cohort study
    Anna Beltrame
    Department of Medical and Morphological Research, University of Udine, Italy
    Int J STD AIDS 17:260-6. 2006
    ..45, C.I. = 1.20-16.81, P = 0.03). Risk of candidal vaginal colonization episodes in HIV-infected women significantly increase when CD4(+) T-lymphocytes are less than 100...
  75. ncbi Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso
    Salvatore Pignatelli
    St Camille Medical Center, Ouagadougou, Burkina Faso
    Trop Med Int Health 11:350-7. 2006
    ..To identify factors predicting uptake of voluntary HIV counselling and testing in pregnant women...
  76. ncbi Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 41:180-5. 2006
    ..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial...
  77. ncbi Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery
    Federico Pea
    Institute of Clinical Pharmacology and Toxicology, Department of Experimental and Clinical Pathology and Medicine, Medical School, University of Udine, Italy
    Int J Antimicrob Agents 27:15-9. 2006
    ....
  78. ncbi Gamma delta T cells and resolution of cytomegalovirus infection in an HIV/HCV coinfected patient after liver transplantation
    Gianpiero D'Offizi
    Transplantation 80:1523-4. 2005
  79. ncbi Natural history of chronic hepatitis B in co-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
    J Hepatol 44:S65-70. 2006
    ....
  80. pmc Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
    ....
  81. ncbi Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects
    Massimo Puoti
    Clinica di Malattie Infecttive e Tropicali, Università degli studi de Brescia, AO Spedali Civili dei Brescia
    AIDS Rev 4:27-35. 2002
    ..Highly Active Anti-Hepatitis B Therapy will probably soon come of age...